Chromosomal microarray better informs brain tumor diagnosis: Robert Jenkins, M.D., Ph.D.
Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray assay outperforms other tests for brain tumor analysis. The microarray aligns with the World Health Organization's latest classification of central nervous system t
Episode 211 of the Answers from the Lab podcast, hosted by Mayo Clinic Laboratories, titled "Chromosomal microarray better informs brain tumor diagnosis: Robert Jenkins, M.D., Ph.D." was published on February 21, 2023 and runs 23 minutes.
February 21, 2023 ·23m · Answers from the Lab
Summary
Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray assay outperforms other tests for brain tumor analysis. The microarray aligns with the World Health Organization's latest classification of central nervous system tumors.
Episode Description
(00:31)
Could you provide a little bit about yourself and your background?
(02:04)
Could you provide an overview of the chromosomal microarray assay?
(05:49)
Why should the chromosomal microarray assay be used over other available assays, such as FISH?
(08:56)
Does the chromosomal microarray provide good benefits in terms of gain of 7 and loss of 10, and EGFR amplification?
(12:03)
What's the value of utilizing the test alongside a neuro-specific NGS panel, such as Mayo Clinic Laboratories' NONCP panel?
(17:20)
How are the results used in patient care?
(19:41)
Is there anything else you feel it's important to highlight?
Similar Episodes
Apr 5, 2026 ·6m
Apr 2, 2026 ·5m
Mar 29, 2026 ·7m
Mar 19, 2026 ·5m
Mar 15, 2026 ·7m
Mar 9, 2026 ·12m